Orphan designation: Plerixafor Treatment of acute respiratory distress syndrome (ARDS), 19/02/2024 Positive

Overview

Metadata
Provider: 
European Medicines AgencyEuropean Medicines Agency
URL: 
https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2899https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-24-2899
Retrieved on: 
Thursday, April 18, 2024
Information
Tags: 
Patient, Committee, Acute respiratory distress syndrome, EMA, IRIS, COMP, European Commission, Marketing, Medicine, Pharmaceutical industry
Geotags: 
RARE, ARDS, EU
Summary
Key Points: 
  • Overview
    This medicine was designated as an orphan medicine for the treatment of acute respiratory distress syndrome on 19 February 2024.
  • Orphan designation does not mean the medicine is available or authorised for use.
  • All medicines, including designated orphan medicines, must be authorised before they can be marketed and made available to patients in the EU.
  • EU register of orphan medicines
    The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:
Copyright: 
2024 European Medicines Agency. All Rights Reserved.